Research Analysts Set Expectations for MIST Q1 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for Milestone Pharmaceuticals in a report issued on Tuesday, April 1st. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.11) per share for the quarter, up from their previous estimate of ($0.18). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.44) EPS, Q1 2026 earnings at ($0.23) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.85) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at ($0.63) EPS, FY2027 earnings at ($0.63) EPS, FY2028 earnings at ($0.30) EPS, FY2028 earnings at ($0.30) EPS, FY2029 earnings at $0.28 EPS and FY2029 earnings at $0.28 EPS.

Several other research analysts also recently weighed in on MIST. TD Securities downgraded Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. TD Cowen lowered Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday.

Milestone Pharmaceuticals Stock Performance

Milestone Pharmaceuticals stock opened at $0.70 on Friday. Milestone Pharmaceuticals has a fifty-two week low of $0.67 and a fifty-two week high of $2.75. The company has a market capitalization of $37.12 million, a price-to-earnings ratio of -0.86 and a beta of 1.38. The stock has a fifty day moving average of $1.87 and a two-hundred day moving average of $1.81. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40.

Institutional Trading of Milestone Pharmaceuticals

Large investors have recently modified their holdings of the business. Jones Financial Companies Lllp increased its holdings in Milestone Pharmaceuticals by 1,000.0% during the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after purchasing an additional 10,000 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Milestone Pharmaceuticals during the fourth quarter worth approximately $170,000. PVG Asset Management Corp acquired a new stake in shares of Milestone Pharmaceuticals during the third quarter worth approximately $46,000. Northern Trust Corp increased its stake in shares of Milestone Pharmaceuticals by 112.6% in the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock worth $137,000 after buying an additional 30,772 shares during the last quarter. Finally, Toronto Dominion Bank acquired a new stake in Milestone Pharmaceuticals in the fourth quarter valued at $1,770,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.